Stay updated with breaking news from Thomas Powles. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.
Find out why Thomas Powles is on the TIME100 Health list.
Find out why Thomas Powles is on the TIME100 Health list.
Testing for tumor DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows.
Researchers found that the enfortumab vedotin-pembrolizumab group had significantly longer progression-free survival than the chemotherapy group.